Tag: PAA

PharmAust ASX PAA new lead researcher phase IIb monepantel trial canine lymphoma Dr Kim Agnew

PharmAust secures new lead researcher for phase IIb monepantel trial on canine lymphoma

Clinical stage oncology company PharmAust (ASX: PAA) has appointed Dr Kim Agnew as the new principal investigator for its phase IIb veterinary clinical trial testing anti-cancer drug monepantel in pet...
PharmAust ASX PAA 2021 phase II trial canines B-Cell Lymphoma MPL Monepantel

PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19

Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma. During the March quarter, PharmAust...
PharmAust ASX PAA Phase IIb monepantel trial identifies therapeutic window treatment canine lymphoma

PharmAust’s phase IIb monepantel trial identifies therapeutic window for treatment of canine lymphoma

An interim analysis of a phase IIb trial conducted by clinical-stage oncology company PharmAust (ASX: PAA) has provided supportive evidence of a therapeutic window for lead drug candidate monepantel t...
PharmAust ASX PAA R&D tax incentive refund research development Epichem Pitney Pharmaceuticals

PharmAust secures $750,000 R&D refund from ATO

Clinical-stage oncology company PharmAust (ASX: PAA) has received a hefty rebate from the Australian Tax Office under the national research and development tax incentive scheme for the work of its who...
PharmAust MPL MPLS drug candidates antiviral activity SARS-CoV2 ASX PAA

PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2

Further pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 ...
PharmAust ASX PAA Phase IIb clinical trial Monepantel pet dogs treatment Naïve B Cell Lymphoma

PharmAust reveals early results from phase IIb canine lymphoma trial

PharmAust (ASX: PAA) has completed assessment of the first five dogs in a phase IIb trial of its anti-cancer drug monepantel on treatment-naïve B cell lymphoma in canines, revealing only minimal side ...
PharmAust ASX PAA Epichem Thermaquatica for the Oxidative Hydrothermal Dissolution technology

PharmAust subsidiary Epichem to advance ‘world first’ waste-to-fuel conversion technology

PharmAust’s (ASX: PAA) subsidiary Epichem has inked a licencing deal that will see it research, develop and promote a disruptive flow reactor technology that converts waste to fuel. Thermaquatica f...
PharmAust ASX PAA Monepantel dogs clinical trial cancer Naïve B Cell Lymphoma MPL tablets

PharmAust calls for more dogs for anti-cancer canine drug trial

Biotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its lead anti-cancer drug monepantel (MPL) on canine lymphoma and has put a call out for more dogs to p...
PharmAust PAA ASX canine participants Phase IIb lymphoma trial drug monepantel

PharmAust seeks more canine participants for phase IIb lymphoma trial using lead drug monepantel

Biotechnology firm PharmAust (ASX: PAA) is looking to recruit more canines with B-cell lymphoma to a new phase IIb trial evaluating a re-formulation of its lead anti-cancer drug monepantel, which has ...
PharmAust PAA ASX monepantel MPL canine dog cancer B cell lymphoma quarterly December 2020

PharmAust begins next trial using monepantel to treat canines with lymphoma

Following a successful phase IIa trial using monepantel (MPL) to treat canine lymphoma, PharmAust’s (ASX: PAA) phase IIb study has begun. The recent phase IIa trial using monepantel to treat B-cell...
PharmAust ASX PAA September quarter drug monepantel FightMND SARS-CoV-2

PharmAust posts strong September quarter led by advances in development of lead drug monepantel

Oncology company PharmAust (ASX: PAA) has posted a strong quarter of business activity, led by a hefty grant last month for a phase 1 clinical trial to investigate the effects of lead drug monepantel ...
Olivia Newton-John Cancer Research Institute Pharmaust monepantel anti cancer mechanism ASX PAA

Olivia Newton-John Cancer Research Institute evaluates PharmAust’s anti-cancer drug

Clinical-stage oncology company PharmAust (ASX: PAA) has announced the Olivia Newton-John Cancer Research Institute (ONJCRI) is investigating the anti-cancer mechanism of its flagship drug candidate m...
PharmAust ASX PAA testing monepantel sulfone drugs COVID-19 SARS-CoV-2

PharmAust advances testing of monepantel drugs against COVID-19

PharmAust (ASX: PAA) is set to test the ability of its monepantel and monepantel sulfone drugs on their ability to inhibit coronavirus SARS-CoV-2 infection, the virus behind the COVID-19 global pandem...
FightMND Motor Neurone Disease Monepantel PharmAust ASX PAA

PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease

Motor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a grant for a Phase 1 trial to examine the effects of its flagship drug candidate monepantel on the disea...
PharmAust ASX PAA monepantel 2020 anti cancer drug Epichem

PharmAust lays out market strategy for lead drug monepantel

Oncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developments of its lead drug candidate, monepantel (MPL). PharmAust is currently progressing the drug in...
PharmAust ASX PAA monepantel anti-viral potential fight against COVID-19video

PharmAust confirms monepantel’s anti-viral potential in fight against COVID-19

Determined to become one of the first companies to develop an active treatment for COVID-19, oncology company PharmAust (ASX: PAA) has reported it has successfully repeated a second round of in-vitro ...
PharmAust ASX PAA Epichem waste fuels technology Obsidian Minerals

PharmAust subsidiary Epichem signs JV to develop waste-to-fuels technology

PharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Western Australia-based private company Obsidian Minerals to develop a novel and disruptive waste-to-fuels...
PharmAust ASX PAA monepantel MPL cancer COVID-19

PharmAust trims losses as monepantel drug development progresses

Oncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated many achievements in the overall development of its lead cancer drug, monepantel (MPL). MPL is a vet...
PharmAust ASX PAA SARS-CoV-2 Monepantel Human Respiratory Calu-3 cells in vitro

PharmAust research shows monepantel can inhibit progression of SARS-CoV-2 virus

Preliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel sulfone have demonstrated that application of the drugs on human respiratory cells can inhibit the pro...
PharmAust clinical trials monepantel COVID-19 canines cancer ASX PAA

PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer

Clinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter performance to lead drug monepantel and monepantel sulfone which has shown “remarkable” early results agai...
PharmAust ASX PAA cancer drug monepantel COVID-19

Repeat experiment proves PharmAust’s lead cancer drug can reduce infectivity of COVID-19 cells

A repeat preliminary evaluation of PharmAust’s (ASX: PAA) lead cancer drug monepantel and monepantel sulfone has found it can reduce transmission in cells infected with the current SARS-CoV-2 strain o...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS